15728-05-9

Usage

Uses

Used in Organic Chemical Synthesis:
3-(4-NITRO-1,3-DIOXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PROPIONIC ACID is used as a key intermediate in the synthesis of various organic compounds. Its unique structure allows for the formation of different functional groups, making it a versatile building block in the development of new molecules.
Used in Pharmaceutical Research:
3-(4-NITRO-1,3-DIOXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PROPIONIC ACID is used as a starting material in the development of new pharmaceuticals. Its potential pharmacological activities make it a promising candidate for the treatment of various diseases. Researchers are actively exploring its properties to discover new therapeutic agents.
Used in Research and Development:
3-(4-NITRO-1,3-DIOXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PROPIONIC ACID is used in research and development laboratories to study its chemical properties and potential applications. Scientists are investigating its reactivity, stability, and interactions with other compounds to gain a deeper understanding of its behavior and possible uses.

InChI:InChI=1/C11H8N2O6/c14-8(15)4-5-12-10(16)6-2-1-3-7(13(18)19)9(6)11(12)17/h1-3H,4-5H2,(H,14,15)/p-1

Upstream product

• 641-70-3 3-nitrophthalic acid anhydride 
• 107-95-9 3-amino propanoic acid 

Relevant academic research and scientific papers

Sulfonium ylides 7. Influence of substituents in the imide fragment on the regioselectivity of intramolecular cyclization of phthalimido-containing keto-stabilized sulfonium ylides

The intramolecular cyclization of keto-stabilized sulfonium ylides obtained from β-alanine and containing various imide fragments was studied. On heating in toluene in the presence of PhCO2H, ylides containing a phthalimide moiety are converted into indolizidine-2,6-dione derivatives, whereas those incorporating a 4-methyl-1,2,3,6-tetrahydrophthalimide or pyrrolidine-2,5-dione moieties do not undergo cyclization.

Method of inhibiting binding of nerve growth factor to p75 NTR receptor

The present invention relates to compositions which inhibit the binding of nerve growth factor to the p75NTRcommon neurotrophin receptor and methods of use thereof. In one embodiment, the compound which inhibits binding of nerve growth factor to p75NTRcomprises, particularly when bound to nerve growth factor, at least two of the following: (1) a first electronegative atom or functional group positioned to interact with Lys34of nerve growth factor; (2) a second electronegative atom or functional group positioned to interact with Lys95of nerve growth factor; (3) a third electronegative atom or functional group positioned to interact with Lys88of nerve growth factor; (4) a fourth electronegative atom or functional group positioned to interact with Lys32of nerve growth factor; and (5) a hydrophobic moiety which interacts with the hydrophobic region formed by Ile31, Phe101and Phe86of nerve growth factor.